220 related articles for article (PubMed ID: 33408885)
1. Application of Biomarkers for the Prediction and Diagnosis of Bone Metastasis in Breast Cancer.
Liu F; Ke J; Song Y
J Breast Cancer; 2020 Dec; 23(6):588-598. PubMed ID: 33408885
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Risk factors, prognostic factors, and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast: a population-based study.
Huang Z; Hu C; Liu K; Yuan L; Li Y; Zhao C; Hu C
BMC Cancer; 2020 Nov; 20(1):1145. PubMed ID: 33238981
[TBL] [Abstract][Full Text] [Related]
4. Detection of Bone Metastases in Breast Cancer (BC) Patients by Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b), a Bone Resorption Marker and Serum Alkaline Phosphatase (ALP), a Bone Formation Marker, in Lieu of Whole Body Skeletal Scintigraphy with Technetium99m MDP.
Sarvari BK; Sankara Mahadev D; Rupa S; Mastan SA
Indian J Clin Biochem; 2015 Jan; 30(1):66-71. PubMed ID: 25646043
[TBL] [Abstract][Full Text] [Related]
5. Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study.
Jakob A; Zahn MO; Nusch A; Werner T; Schnell R; Frank M; Hamm N; Däßler KU; Losem C; Welslau M; Hoevel P; Potthoff K
J Bone Oncol; 2022 Apr; 33():100420. PubMed ID: 35340302
[TBL] [Abstract][Full Text] [Related]
6. Is it sufficient to evaluate metastatic bone involvement in breast cancer using SPECT/CT? A new approach of SPECT/CT-guided targeted bone marrow biopsy.
Li X; An C; Zhang W
BMC Cancer; 2022 Jun; 22(1):614. PubMed ID: 35659208
[TBL] [Abstract][Full Text] [Related]
7. Diagnosing and Prognosing Bone Metastasis in Prostate Cancer: Clinical Utility of Blood Biomarkers.
Yamamichi G; Kato T; Uemura M; Nonomura N
Anticancer Res; 2023 Jan; 43(1):283-290. PubMed ID: 36585196
[TBL] [Abstract][Full Text] [Related]
8. Risk stratification system and visualized dynamic nomogram constructed for predicting diagnosis and prognosis in rare male breast cancer patients with bone metastases.
Gao B; Ou XL; Li MF; Wang MD; Huang F
Front Endocrinol (Lausanne); 2022; 13():1013338. PubMed ID: 36440188
[TBL] [Abstract][Full Text] [Related]
9. Cytomorphological evaluation of non-haematopoietic malignancies metastasizing to the bone marrow.
Gajendra S; Sharma R
Am J Blood Res; 2023; 13(1):1-11. PubMed ID: 36937461
[TBL] [Abstract][Full Text] [Related]
10. Application of "omics" sciences to the prediction of bone metastases from breast cancer: State of the art.
Gentile M; Centonza A; Lovero D; Palmirotta R; Porta C; Silvestris F; D'Oronzo S
J Bone Oncol; 2021 Feb; 26():100337. PubMed ID: 33240786
[TBL] [Abstract][Full Text] [Related]
11. Detection of disseminated tumor cells in the bone marrow of breast cancer patients using multiplex gene expression measurements identifies new therapeutic targets in patients at high risk for the development of metastatic disease.
Siddappa CM; Watson MA; Pillai SG; Trinkaus K; Fleming T; Aft R
Breast Cancer Res Treat; 2013 Jan; 137(1):45-56. PubMed ID: 23129172
[TBL] [Abstract][Full Text] [Related]
12. Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients.
Lee KH; Lee KJ; Kim TY; Hutomo F; Sun HJ; Cheon GJ; Park SI; Cho SW; Im SA
J Bone Miner Res; 2020 Oct; 35(10):1838-1849. PubMed ID: 32379371
[TBL] [Abstract][Full Text] [Related]
13. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
D'Oronzo S; Coleman R; Brown J; Silvestris F
J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
[TBL] [Abstract][Full Text] [Related]
14. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
Zulauf N; Brüggmann D; Groneberg D; Oremek GM
Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
[TBL] [Abstract][Full Text] [Related]
15. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse.
Siddappa CM; Pillai SG; Snider J; Alldredge P; Trinkaus K; Watson MA; Aft R
Breast Cancer Res Treat; 2019 Nov; 178(2):317-325. PubMed ID: 31432366
[TBL] [Abstract][Full Text] [Related]
16. Biochemical-markers for the diagnosis of bone metastasis: a clinical review.
Huang Q; Ouyang X
Cancer Epidemiol; 2012 Feb; 36(1):94-8. PubMed ID: 21474411
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow mammaglobin-1 (SCGB2A2) immunohistochemistry expression as a breast cancer specific marker for early detection of bone marrow micrometastases.
Talaat IM; Hachim MY; Hachim IY; Ibrahim RAE; Ahmed MAER; Tayel HY
Sci Rep; 2020 Aug; 10(1):13061. PubMed ID: 32747636
[TBL] [Abstract][Full Text] [Related]
18. Risk factors and prognostic factors for inflammatory breast cancer with bone metastasis: A population-based study.
Gao T; Shao F
J Orthop Surg (Hong Kong); 2021; 29(2):23094990211000144. PubMed ID: 34060362
[TBL] [Abstract][Full Text] [Related]
19. "The use of bisphosphonates to treat skeletal complications in solid tumours".
D'Oronzo S; Wood S; Brown JE
Bone; 2021 Jun; 147():115907. PubMed ID: 33676057
[TBL] [Abstract][Full Text] [Related]
20. Predictive models for the risk and prognosis of bone metastasis in patients with newly-diagnosed esophageal cancer: A retrospective cohort study.
Yuan B; Lu H; Hu D; Xu K; Xiao S
Front Surg; 2022; 9():1014781. PubMed ID: 36713649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
